These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840 [TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of the Plasmodium falciparum Pf332-DBL domain in combination with different adjuvants. Du C; Nilsson S; Lu H; Yin J; Jiang N; Wahlgren M; Chen Q Vaccine; 2010 Jul; 28(31):4977-83. PubMed ID: 20653104 [TBL] [Abstract][Full Text] [Related]
26. Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720. Lawrence GW; Saul A; Giddy AJ; Kemp R; Pye D Vaccine; 1997 Feb; 15(2):176-8. PubMed ID: 9066035 [TBL] [Abstract][Full Text] [Related]
27. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice. Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232 [TBL] [Abstract][Full Text] [Related]
28. [Construction and expression of Plasmodium berghei chimeric protein in Pichia pastoris and its immunogenicity in mice]. Cao Y; Zhang DM; Pan WQ Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2008 Oct; 26(5):327-31. PubMed ID: 19157293 [TBL] [Abstract][Full Text] [Related]
30. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. Carvalho LJ; Alves FA; Bianco C; Oliveira SG; Zanini GM; Soe S; Druilhe P; Theisen M; Muniz JA; Daniel-Ribeiro CT Clin Diagn Lab Immunol; 2005 Feb; 12(2):242-8. PubMed ID: 15699417 [TBL] [Abstract][Full Text] [Related]
31. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara. Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237 [TBL] [Abstract][Full Text] [Related]
32. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults. Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J; Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Yazdani SS; Shakri AR; Mukherjee P; Baniwal SK; Chitnis CE Vaccine; 2004 Sep; 22(27-28):3727-37. PubMed ID: 15315853 [TBL] [Abstract][Full Text] [Related]
35. A single injection of 19 kda carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 (PyMSP1(19)) formulated with Montanide ISA and CpG ODN induces protective immune response in mice. Hirunpetcharat C; Mahakunkijcharoen Y; Jeamwattanalert P; Kittigul L; Mahannop P; Pichyangkul S Asian Pac J Allergy Immunol; 2011 Sep; 29(3):252-9. PubMed ID: 22053595 [TBL] [Abstract][Full Text] [Related]
36. Immunoenhancing effects of Montanide ISA oil-based adjuvants on recombinant coccidia antigen vaccination against Eimeria acervulina infection. Jang SI; Lillehoj HS; Lee SH; Lee KW; Park MS; Bauchan GR; Lillehoj EP; Bertrand F; Dupuis L; Deville S Vet Parasitol; 2010 Sep; 172(3-4):221-8. PubMed ID: 20541870 [TBL] [Abstract][Full Text] [Related]
37. Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques. Mahdi Abdel Hamid M; Remarque EJ; van Duivenvoorde LM; van der Werff N; Walraven V; Faber BW; Kocken CH; Thomas AW PLoS One; 2011; 6(5):e20547. PubMed ID: 21655233 [TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. Macete E; Aponte JJ; Guinovart C; Sacarlal J; Ofori-Anyinam O; Mandomando I; Espasa M; Bevilacqua C; Leach A; Dubois MC; Heppner DG; Tello L; Milman J; Cohen J; Dubovsky F; Tornieporth N; Thompson R; Alonso PL Trop Med Int Health; 2007 Jan; 12(1):37-46. PubMed ID: 17207146 [TBL] [Abstract][Full Text] [Related]
39. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Pichyangkul S; Gettayacamin M; Miller RS; Lyon JA; Angov E; Tongtawe P; Ruble DL; Heppner DG; Kester KE; Ballou WR; Diggs CL; Voss G; Cohen JD; Walsh DS Vaccine; 2004 Sep; 22(29-30):3831-40. PubMed ID: 15364429 [TBL] [Abstract][Full Text] [Related]
40. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Nardin EH; Oliveira GA; Calvo-Calle JM; Wetzel K; Maier C; Birkett AJ; Sarpotdar P; Corado ML; Thornton GB; Schmidt A Infect Immun; 2004 Nov; 72(11):6519-27. PubMed ID: 15501783 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]